Maternal Fetal ScreenSM | T1:
A Breakthrough in
Prenatal Screening

Did you know?

ACOG and the Preeclampsia Foundation recently endorsed bipartisan legislation to strengthen state efforts to prevent maternal deaths. The Preventing Maternal Deaths Act will support states in establishing or expanding their mortality review efforts.

Maternal Fetal ScreenSM | T1 is the only test to combine first-trimester aneuploidy risk assessment with early onset preeclampsia (EOPE) in one report—providing your patient with a comprehensive personalized risk result as early as 10 weeks’ gestation.

Maternal Fetal ScreenSM | T1 casts a wide net for maternal and fetal issues, such as aneuploidy, preeclampsia, low birth weight, fetal loss, and stillbirth. 

The Most Comprehensive Overall Pregnancy Health Evaluation

Maternal Fetal ScreenSM | T1 analyzes five biochemical markers in the maternal blood sample—free Beta hCG, PAPP-A (pregnancy-associated plasma protein-A), AFP (alpha fetoprotein), PIGF (placental growth factor) and dimeric inhibin A (DIA)—together with an ultrasound (NT, NB, and UtAD-PI) to provide quantitative risk assessments for trisomies 21, 18 and 13 and EOPE. 

Identify At-Risk Patients Sooner for Further Testing

The American Congress of Obstetrics and Gynecologists (ACOG) and The Society for Maternal-Fetal Medicine (SMFM) continue to support traditional screening for the average obstetric population, reserving NIPT for those at increased risk for common aneuploidies.

Maternal Fetal ScreenSM | T1 affords excellent aneuploidy detection while providing an overall pregnancy health evaluation.

Test Specifications for Maternal Fetal ScreenSM | T1


Test Specifications for Maternal Fetal Screening
Turnaround time for Maternal Fetal ScreenSM | T1 is 24–48 hours from sample receipt at the laboratory. 

DISCLAIMER: This test is a part of a lab service offering provided by Eurofins NTD, LLC. This test was developed and its performance characteristics determined by Eurofins NTD, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health. The test results do not eliminate the possibility that this pregnancy may be associated with birth defects or pregnancy complications including preeclampsia, pre-term delivery and low birth weight. The multiple of the median and risk results provided in the test report are dependent on the accuracy of the demographic and ultrasound information provided. The ordering physician should ensure that the ultrasound information has been obtained from a sonographer who is credentialed by and participating in a uterine artery Doppler quality review program such as FMF. Eurofins NTD, LLC. assumes no responsibility for ensuring that the ultrasound information has been obtained by a properly credentialed sonographer, including verification or updates to credentialing status.